Puma Biotechnology, Inc. (NASDAQ: PBYI) reported first-quarter 2024 adjusted loss of 5 cents per share, which was narrower than the Zacks Consensus Estimate of a loss of 16 cents. In the year-ago quarter, the company had reported adjusted earnings of 9 cents.
Related Keywords
United States , China , , Ligand Pharmaceuticals Incorporated , Puma Biotechnology Inc , Pharmaceuticals Inc , Voyager Therapeutics Inc , Zacks Consensus Estimate , Puma Biotechnology , Zacks Rank , Voyager Therapeutics , Ligand Pharmaceuticals , Strong Buy , Voyager Therapeutic ,
vimarsana.com © 2020. All Rights Reserved.